Latest News & Blog

Inspiring & original thinking. And, the latest news about us.

THINKING

Welcome to Well Filtered™

A blog series dedicated to unearthing the ideas, perspectives, and innovations that matter most in kidney health.

Getting FDA approval, a base hit. Getting reimbursement, that’s the ball game. 06.28.22

Is there real value in value-based care? 02.08.22

A SPECIAL, NEW YEAR INVESTIGATIVE BLOG: Making Sense of Population Health, Precision Medicine & Value-Based Care with Mount Sinai’s Dr. Arshad Rahim 01.06.22

An “Inside Look” at Precision Medicine, Cardiovascular & Kidney Disease: We Get It Straight from Bayer’s, Dr. Amit Sharma 10.26.21

A “How To” Playbook for Disrupting Kidney Care: Our Live Chat with the National Kidney Foundation’s Chief Medical Officer 09.20.21

Are Kidney-Focused Clinical Studies Finally Hitting Their Groove? The Trials to Watch & Why 08.10.21

3 Ways We’re Translating Lessons Learned in Cancer to Help Fix the Kidney Care Model 7.27.21

6 Tipping Point Innovations in Kidney Care: A Leading Expert Shares His POV 6.28.21

Why a Shift in Thinking from Kidney Disease to Kidney Health is Mission-Critical. A Candid Conversation with NKF’S Former President & Board Member, Holly Kramer. 6.02.21

NEWS

RenalytixAI Utah Commercial Laboratory Facility Achieves ISO 13485 Certification 04.27.20
NEW YORK, April 27, 2020 /PRNewswire/ -- Renalytix AI plc (LSE: RENX), the AIM-traded developer of clinical grade artificial intelligence in vitro diagnostics for kidney disease, announced today that it has received ISO 13485:2016 certification for its development and commercial laboratory

Read More
KidneyIntelX™ to Predict Major Adverse Kidney Events in COVID-19 Patients 04.20.20
NEW YORK, April 20, 2020 /PRNewswire/ -- Renalytix AI plc (LSE: RENX), the AIM-traded developer of clinical grade artificial intelligence in vitro diagnostics for kidney disease, announces that the KidneyIntelX™ platform will be used by investigators from the Icahn School of Medicine

Read More
RenalytixAI Announces Podium Presentation and Publication on “Evaluation of Payer Budget Impact Associated with the Use of Artificial Intelligence in vitro Diagnostic, KidneyIntelX™, to Modify DKD Progression” 03.24.20
Oral presentation accepted for Late Breaking session of the National Kidney Foundation Spring Clinical Meeting Accompanying abstract accepted for publication in American Journal of Kidney Disease NEW YORK, March 24, 2020 /PRNewswire/ -- Renalytix AI plc (LSE: RENX), the AIM-traded developer of

Read More
RenalytixAI CEO to Speak at the 40th Annual Cowen Health Care Conference 03.02.20
NEW YORK, March 2, 2020 /PRNewswire/ -- Renalytix AI plc (AIM: RENX), a developer of artificial intelligence enabled clinical diagnostics for kidney disease, announces it will be presenting at the Cowen 40th Annual Health Care Conference taking place on March 1-4, 2020, at the Boston Marriott

Read More
Medicare Sets National Price for KidneyIntelX™ 12.03.19
NEW YORK, Dec. 3, 2019 /PRNewswire/ -- Renalytix AI plc (LSE: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announced today that the Centers for Medicare and Medicaid Services ("CMS") has released the Final 2020 Clinical Laboratory Fee Schedule

Read More
RenalytixAI Partners with Capital District Physicians’ Health Plan, Inc. on KidneyIntelX™ 10.17.19
Effective October 16, KidneyIntelX will be covered for reimbursement for qualified members NEW YORK, Oct. 17, 2019 /PRNewswire/ -- Renalytix AI plc (AIM: RENX), a developer of artificial intelligence enabled clinical diagnostics for kidney disease, announces that Capital District Physicians'

Read More
Johns Hopkins Director of Nephrology Chirag Parikh Joins RenalytixAI Board 10.14.19
NEW YORK, Oct. 14, 2019 /PRNewswire/ -- Renalytix AI plc (AIM: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announced today the appointment of leading kidney investigator and clinician Dr. Chirag Parikh to the Renalytix board. Dr.

Read More
RenalytixAI Appoints Thomas McLain as President and Chief Commercial Officer 07.29.19
Company expands leadership team with focus on reimbursement for artificial intelligence clinical in vitro diagnostic, KidneyIntelX™ NEW YORK, July 29, 2019 /PRNewswire/ -- Renalytix AI plc (LON: RENX), a developer of artificial intelligence-enabled diagnostics for kidney disease, announces the

Read More
RenalytixAI Releases Positive Interim Results in Expanded Validation Study for KidneyIntelX™ 07.09.19
Data development plan review continues with FDA under Breakthrough Device designation process; Performance meets or exceeds targets for identifying rapid kidney function decline in patients with Type 2 diabetes and existing chronic kidney disease NEW YORK, July 9, 2019 /PRNewswire/ -- Renalytix AI

Read More
U.S. CPT® Code Granted for KidneyIntelX™ 07.01.19
CPT Code a key component for reimbursement from private medical insurance and Medicare NEW YORK, July 1, 2019 /PRNewswire/ -- Renalytix AI plc (LON: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announced today that the American Medical

Read More

...